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Abstract
Background: The urokinase receptor (uPAR) governs several functions necessary during invasion
and metastasis such as motility, degradation of the extracellular matrix and adhesion. This receptor
has been recently associated with clinical prostate cancer progression. Experimentally, inhibition of
uPAR reduces colonization of extra-prostatic sites in animal models. Our objective in this study
was to compare uPAR expression in orthotopic vs. metastatic foci in vivo and to examine at the
cellular level how uPAR might promote early stages of metastasis.
Results: We show that uPAR staining is significantly greater in regional lymph node metastases
than in the intraprostatic tumor mass. Using transient over-expression, we found that uPAR
increases in vitro motility and chemotactic invasion. Finally, we demonstrate that uPAR is up-
regulated by a significant subpopulation prostate cancer cells following matrix detachment and
maintenance in suspension and we provide evidence that prostate cancer cells with elevations in
uPAR have an enhanced resistance to anoikis.
Conclusion: These data provide new evidence that uPAR can be induced by cancer cells during
metastasis in vivo and that this elevated uPAR enhances resistance to anoikis in vitro.
Background
Successful metastasis entails acquisition of phenotypic
qualities that may be atypical to the majority of cells
within the primary tumor mass [1]. These traits include
enhanced motility, increased degradation of the extracel-
lular matrix, altered adhesion and the ability to survive
apart from the homeotypic environment [2]. Although
large numbers of tumor cells begin the invasive process,
those cell numbers are greatly reduced through selection
for the ability to survive or grow through the sequences of
metastatic progression [3,4]. Much remains to be learned
about specific mechanisms which permit regional metas-
tasis followed by dissemination to distant sites; however
these mechanisms are generally understood to incorpo-
rate responses to exogenous growth factors and cytokines,
regulation of matrix proteases, interaction with stromal
elements in the tumor microenvironment, angiogenesis,
resistance to apoptosis and avoidance of immune surveil-
lance [5,6].
uPAR regulates cancer dissemination in a variety of ways.
By binding to its enzymatic ligand uPA which generates
plasmin, uPAR directs extracellular matrix (ECM) degra-
dation necessary for cancer cell invasion. By placing uPAR
at the leading edge of directional migration, cells are able
to limit the scope of this matrix proteolysis. uPAR also
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interacts with the ECM through its binding to vitronectin
and associations with various integrins and other extracel-
lular proteins. These associations allow uPAR to use the
ECM as a scaffold to support cell motility, spreading and
adhesion during tumor invasion [7]. uPAR also generates
discrete signaling cascades most likely through contact
with transmembrane proteins. These internal signals have
been reported to induce growth, actin cytoskeletal rear-
rangements, and protection from apoptosis [7-9].
Recently, uPAR overexpression was shown to inhibit
anoikis in non-transformed human retinal pigment epi-
thelial cells. This effect resulted from MAPK and phos-
phatidylinositol 3-kinase (PI3K) upregulation of the Bcl-
xL anti-apoptotic factor [10].
With regard to human prostate cancer, elevations in a sol-
uble form of plasma uPAR is associated with tumor devel-
opment, progression and worse prognosis [11-13].
Tumor-associated uPA and uPAR have been reported to be
preferentially expressed in prostate adenocarcinoma cells
vs. prostatic stroma [14]; however, this cancer cell expres-
sion is not consistently found in patient samples [15] sug-
gesting that uPAR expression in primary tumor tissue may
be very low or negative in some instances. The prognostic
significance of uPAR expression in prostate cancer metas-
tases such as bone has not been reported; however human
gastric cancer patients with elevated uPAR expression on
tumor cells which disseminated to bone marrow have
shorter disease-free and overall survival [16].
In animal models of prostate cancer, pharmacological
inhibition of uPAR reduced bone colonization of PC3
cells when the cells were administered directly into the
vasculature [17] and lung, liver and lymph node metas-
tases are reduced by anti-uPAR antibody treatments in a
subcutaneous rat prostate model [18]. Pulukuri et al. [19]
have recently demonstrated that shRNAs for uPA and
uPAR almost completely inhibit established orthotopic
tumor growth; however, little is known about the expres-
sion of uPAR during prostate cancer progression from the
orthotopic environment to early metastatic sites.
In this report, we sought to determine if a relationship
exists between uPAR expression and development of early
metastatic foci in vivo. Next, we addressed at the cellular
level, how uPAR overexpression in a relatively small frac-
tion of prostate cancer cells might promote invasion and
metastasis. We found that transient overexpression of
uPAR promotes selective increases in both in vitro motility
and chemotactic invasion. In addition, we link for the first
time uPAR with the ability of tumor cells to resist anikois
– the induction of apoptosis which follows the loss of
adhesion. Our study indicates that uPAR may be tempo-
rarily overexpressed in a sub-fraction of tumor cells per-
mitting those cells to survive the initial lethal first stages
of metastastic progression.
Results
PC-3M tumors metastasize to regional lymph nodes and 
express increased uPAR
Histologically, PC-3M tumors which developed in the
prostates of nude mice exhibited pleiomorphic morphol-
ogy and a high mitotic index (Figure 1A). The primary
tumor often compressed existing mouse prostatic acini
(Figure 1B). These orthotopic tumors exhibit robust
expression of PCNA indicative of active proliferation (Fig-
ure 1C). Each mouse also developed several metastases to
regional lymph nodes in proximity to the abdominal
aorta. Tumor cells within these lymph nodes developed
discrete foci which were surrounded by lymphatic tissues
(Figure 1D).
The primary tumor and tumor-bearing lymph nodes from
the abdominal region were removed and immunochemi-
cally stained for uPAR. There was little uPAR-positive
staining in the primary tumor mass, indicating that high
uPAR expression is not requisite for establishment or pro-
liferation of the primary tumor in this model (Figure 2A).
PC-3M prostate cancer and metastasis Figure 1
PC-3M prostate cancer and metastasis. PC3M-luc cells (5 × 
105) were orthotopically injected into the prostate of Nu/Nu 
mice. Mice sacrificed at 50 days, prostate tumors were 
removed and prepared for sectioning. A. H&E section of 
orthotopic tumor [400×] mass. Normal glands (N), cancer 
cells (Ca) and mitotic figure (mit) are indicated. B. H&E sec-
tion of tumor [200×] compressing normal glands. C. PCNA 
staining of PC-3M orthotopic tumor [630×]. D. Lymph node 
metastasis [200×] showing cancer cells (Ca) and lymphatic 
tissue (lym).Cancer Cell International 2006, 6:21 http://www.cancerci.com/content/6/1/21
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Staining of tumor cells proliferating within regional
lymph nodes however, revealed multifocal regions pos-
sessing deep staining indicative of uPAR positivity (Figure
2B). Often these metastatic epithelial cells were more het-
erogeneous in size than those in the primary tumor. To
quantitatively compare uPAR expression between primary
and lymph node tumors, tissue sections were randomly
scored to determine the number of uPAR-positive cells.
These data confirmed a highly significant increase in
uPAR positive cells in lymph node metastases compared
with uPAR positive cells in the primary tumors (Figure
2C) in each of the mice.
uPAR confers increased migration and invasive properties 
to transfected PC-3M cells
In order to begin to understand why uPAR might be
enriched in lymph node metastases, we directly compared
uPAR overexpressing (uPAR+) cells with wild-type cells in
vitro in assays designed to mimic some of the processes
required for successful invasion We introduced uPAR into
PC-3M cells by transient tranfection; this method pro-
duced a fraction of uPAR+ cells accompanied by a major-
ity of wild-type uPAR-expressing PC-3M, which was
analogous to our observation in the orthotopic tumor.
To measure migration, cells were applied on top of Fluor-
oBlok transwell chambers. The percentage of uPAR+ cells
which traversed the insert was compared with the percent
of uPAR+ cells remaining in the upper chamber (Table 1)
and results indicated that the enrichment of uPAR+ cells
in the migrating fraction was significant. In addition to
migration, the ability to degrade and invade through
extracellular matrix is a key component in successful early
metastasis. Therefore, we next coated the FluoroBlok
membranes with Matrigel and repeated the assay. We
found that transient uPAR over-expression increased
PC3M invasiveness as the population of invading cells
possessed a much greater percent of uPAR+ cells (Table 1).
In order to determine if transfection itself lead to altered
motility and/or invasion, PC-3M cells expressing EGFP
were transfected using a control plasmid (pEF6/V5 His
lacZ). We found no differences between the percents of β-
uPAR-positive cells in prostate cancer vs. lymph node metas- tases (200× images) Figure 2
uPAR-positive cells in prostate cancer vs. lymph node metas-
tases (200× images). Tumor section images taken from one 
representative mouse and stained with rabbit anti-uPAR 
(399R, American Diagnostica Corp.). A. Little or no uPAR 
staining is apparent in the cancer (Ca) cells within the mouse 
prostate. Image taken at tumor periphery. B. Strong uPAR 
immunoreactivity in metastatic cancer cells (Ca) is seen adja-
cent to lymphatic cells (lym).C. uPAR-positive cells in pros-
tate vs. lymph node (l.n.) metastases in each of 5 mice. Data 
show the total number of uPAR-positive cells counted in 
each prostate and l.n. for each mouse. White bars represent 
primary tumors, black bars represent the l.n. metastases. The 
data for all 5 mice was collectively analyzed using a paired t-
test and the p value was 0.0011.
Table 1: uPAR overexpression enhances directional migration and in vitro invasion of PC-3M cells.
migration invasion
uPAR transfected cells upper
insert
15.0 ± 3.0% 20.0 ± 2.0%
lower
insert
29.4 ± 4.9% 55.0 ± 12.0%
β-gal plasmid transfected (control) cells upper
insert
18.4 ± 3.2% 14.5 ± 2.8%
lower
insert
16.1 ± 1.9% 12.0 ± 1.5%
Table data indicate the percent uPAR+ or β-galactosidase+ cells in the population of cells on the upper membrane (general cell population) and 
lower membrane (cells which successfully traversed the membrane barrier) after a two day period. Data shows the mean and S.E.M of 3 replicate 
experiments.Cancer Cell International 2006, 6:21 http://www.cancerci.com/content/6/1/21
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gal-immunoreactive transfected cells above or beneath the
transwell membranes indicating that the transfection pro-
cedure per se did not account for the observed increase in
motility and invasion (Table 1).
uPAR cell surface expression in induced by culture in 
suspension and is associated with reduced levels of anoikis
One critical barrier to successful metastasis is survival dur-
ing the period of matrix detachment. This detached state
can be modeled in vitro by a forced culture in suspension
[4]. PC-3M cells were incubated in suspension over a
period of 5 days and then assessed by flow cytometry for
uPAR cell surface levels. This experiment demonstrated a
division of the overall cell population with the develop-
ment of a sub-population substantially shifted towards an
increase in uPAR. This shift began after only one day of
suspension (Figure 3A&B). This uPAR-induced sub-popu-
lation peak continued to rise through the second day and
then plateaued until sharply declining after 5 days of cul-
ture. These data indicated that uPAR was induced during
a period of matrix deprivation and suggested the possibil-
ity that this induction might be associated with cell sur-
vival or death.
To pursue this possibility, we investigated the levels of
anoikis in uPAR+ and wild-type PC-3M cells. uPAR-trans-
fected populations of PC-3M were cultured in suspension
over a 3 day period. The time course was limited to the 3
day period to ensure adequate transient expression of the
uPAR protein. Aliquots of cells were removed daily and
scored for number of live, apoptotic and uPAR-over
expressing cells (depicted in Figure 4A). Data from this
experiment revealed that uPAR conferred a protective
effect against developing anikois during 3 days of suspen-
sion incubation (Figure 4B).
Discussion
We have used an in vivo assay of orthotropic metastasis to
regional lymph nodes to begin to dissect the role of uPAR
during early stages of prostate cancer invasion and metas-
tases. This model demonstrated that metastases which
succeed in invading as far as these lymph nodes and then
proliferated within the nodes possessed significantly
greater numbers of uPAR-positive staining cells when
compared to the general population of cells within the
primary tumor. This finding is in accord with a recent
report using cDNA microarray of PC-3M cells to identify
genes upregulated in lymphatic metastasis [20]. The
apparent up-regulation of uPAR in lymph node tumor
colonies suggests that uPAR expression is a phenotypic
trait that is positively selected for during metastasis. While
increased expression could result from the expansion of a
few cells from the primary tumor which over-expressed
the receptor, the increase could also be an inducible phe-
nomenon by which cells expressing little or no uPAR in
the primary tumor induce the uPAR within metastatic
environments. Our in vitro data supports this second pos-
sibility for cancer cells in environments without matrix
attachment as we found some suspended PC-3M cells
gradually up-regulated surface uPAR expression.
In order to identify specific traits that elevated uPAR could
impart to prostate cancer cells which colonized regional
lymph nodes, we transiently transfected uPAR into PC-3M
cells and examined cell behavior in vitro. uPAR-over
expression in a fraction of PC-3M cells conferred
increased directional motility as well as increased inva-
sion. These increases match well with the biology of uPAR
action since uPAR binds to vitronectin and specific beta
integrins allowing it to mediate motility. uPAR also binds
to its enzymatic ligand uPA, which can initiate a cascade
of protease activities which degrade most non-collagen-
ous components of the extracellular matrix [8].
In addition to assessing behaviors necessary to gain access
to the lymphatic vessels, we next considered the possibil-
ity the uPAR might help tumor cells survive within these
vessels. Recent evidence indicates that epithelial cancers
have a high mortality within the circulation [3] due in
large measure to a form of apoptosis induced by matrix
detachment and existence in suspension within the blood
or lymphatic vessels. This form of apoptosis is termed
"anoikis" [21]. We examined the effect of suspension cul-
ture on uPAR cell surface expression by flow cytometry.
Through this experiment, we documented that uPAR is
induced in a distinct subpopulation of the suspended
tumor cells giving rise to two peaks – one of low constitu-
tive uPAR levels and one of uPAR-induction. These two
populations remained until the fifth day of growth in sus-
pension. This novel association of uPAR with culture in
suspension and the well-known link between suspension
and apoptosis, promoted us to next examine the effect of
uPAR overexpression on anoikis resistance. We discovered
that uPAR+ cells were less likely to undergo late-stage
apoptosis over a 3 day period than wild-type PC-3M. Such
a delay in anoikis conferred by uPAR could allow prostate
cancer cells to survive in hematogenous or lymphatic cir-
culation while they migrate to a secondary site. A recent
report by Alfano et al [10] using nontransformed retinal
epithelial cells determined that overexpression of uPAR
can induce resistance to apoptosis including anoikis. Our
data extend this observation to PC-3M prostate cancer
cells and further demonstrates that these cancer cells have
the ability to increase uPAR during suspension. It will now
be important to determine if matrix deprivation leads to
increased uPAR expression in other prostate and other
types of cancer lines and if increased uPAR is accompa-
nied by a complementing increase in uPA.Cancer Cell International 2006, 6:21 http://www.cancerci.com/content/6/1/21
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Although the wild-type PC-3M cell line expresses a mod-
erate level of uPAR – higher levels than PC-3 and lower
levels than PC-3MM2 cells [22] – these cells still under
went a significant degree of apoptosis indicating that the
basal uPAR expression does not confer the degree of resist-
ance offered by over-expression of uPAR. In this report, we
have not attempted to study any anti-apoptotic efficacy of
this basal uPAR expression. Although lowering basal
uPAR could lead to greater aniokis; we believe that this
type of experiment would be more useful in a population
of cells with a high percentage of uPAR-overexpression
and we are currently working towards this goal using a
viral delivery system.
The mechanism through which uPAR expression delays
the onset of anoikis in cancer cells must be elucidated.
uPAR-induced resistance to anoikis in the nontrans-
formed retinal epithelial cells resulted from uPA binding
and activation of MEK/ERK and PI3K/Akt pathways. The
mechanism in prostate cancer cells could originate with
two other protein families, integrins and caveolin, which
have been shown to confer resistance to anoikis in these
cells. Integrins appear to activate a focal adhesion kinase
(FAK)/ phosphoinositide 3-kinase (PI3K)/AKT pathway
[21,23] while caveolin-1 both activates Akt and inhibits
Akt inhibitors [24,25]. Suppression of anoikis can also
result through inhibition of the Jun amino-terminal
Flow cytometry of uPAR cell surface expression shows development of a high uPAR population during suspension culture Figure 3
Flow cytometry of uPAR cell surface expression shows development of a high uPAR population during suspension culture. A. 
Representative flow cytometry histograms of uPAR expression on PC-3M cells over a 5 day time course in forced suspension 
culture. M1 marker shows region greater than background fluorescence (secondary antibody-only control). B. Bars represent 
the mean fluorescent intensity measured in fluorescent counts of uPAR expression in un-fixed PC-3M cells. Cells were incu-
bated in suspension as described in methods for the time periods shown. Bars are the mean of 4 replicates ± s.d.Cancer Cell International 2006, 6:21 http://www.cancerci.com/content/6/1/21
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kinase (JNK) apoptotic pathway by ERK activation [24].
Since uPAR can transduce signals which activate ERK in
MCF-7 breast cancer cells [26], perhaps a similar ERK acti-
vation pathway exists in prostate cancer.
Conclusion
Overall, our in vivo model indicates that there is a selec-
tion for prostate cancer cells with high uPAR expression
during early stages of successful metastasis. In vitro, high
uPAR expression enables prostate tumor cells to become
more motile and to behave more invasively. It also may
provide a temporary inhibition of the highly lethal apop-
totic mechanisms which are triggered during matrix-free
periods that the cancer cell must transition through mov-
ing from primary to metastatic sites. Our finding that
uPAR is induced in some cells during forced-suspension
culture and that uPAR+ cells are more resistant to anoikis
is particularly relevant because few other cell surface pro-
teins have been linked to resisting suspension-induced
anoikis. Further dissection of uPAR functioning during
the metastatic cascade will provide greater insight into
why this receptor is upregulated in regional metastasis.
Methods
Cell culture
PC3M cells (a gracious gift from Dr. Isiah Fidler, MD
Anderson Cancer Center, Houston TX) were maintained
in Minimal Essential Medium with Earle's salts (MEM),
supplemented with 10% fetal bovine serum, 100 units/
mL penicillin, 100 μg/ml streptomycin, and 2.0 mM L-
glutamine.
Intraprostatic tumors
For orthotopic tumor inoculation, 8–10 week old Nu/Nu
male mice (Charles River labs) were anesthetized with iso-
flurane. A low abdominal skin incision cranial to the pre-
pucial glands was made and the seminal vesicles were
carefully exteriorized to expose the dorso-lateral prostate.
Using a 29 gauge insulin syringe, 5 × 105 PC-3M cells sus-
pended in MEM were injected into the dorso-lateral pros-
tate in a 20 uL volume. The seminal vesicles and prostate
were held for one minute to allow the injected cells to set-
tle into the gland and then gently replaced into the
abdominal cavity. Body wall and skin wounds closed were
closed with 5-0 PDS and 5-0 nylon respectively. All ani-
Immunohistochemical staining and quantitation of anoikis in PC-3M cells Figure 4
Immunohistochemical staining and quantitation of anoikis in PC-3M cells. A. uPAR over-expression and apoptosis in PC-3M 
suspension culture. Thin arrow indicates a fluorescence overlay of a live cell (blue) which over-expresses uPAR (green). The 
cell surface uPAR expression is characterized by a stippled staining pattern in the central region of the cell and forms a periph-
eral hallow. This uPAR+ cell is easily distinguishable from a live cell with wild type-uPAR expression (wide arrow). Apoptotic 
cells are shown with nuclear up take of orange-red staining from ethidium bromide. The nuclei demonstrate various degrees of 
condensation while the cell body show no up take of Calcein blue. B. The percentage of apoptosis in cells with wild-type () 
and uPAR+ (▲) are plotted over a 3 day period of suspension. Apoptosis in individual cells was defined as cells which allowed 
ethidium bromide to permeate and stain the nucleus (indicative of a breached plasma membrane) and were unable to accumu-
late Calcein blue methoxyester (fluorescent marker for live cells). uPAR over-expressing cells were identified by immunofluo-
rescent staining using Alexa Fluor 488. Data represent mean ± S.D. of four replicate samples.Cancer Cell International 2006, 6:21 http://www.cancerci.com/content/6/1/21
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mal procedures were approved by the LSU IACUC com-
mittee.
Tumors were allowed to develop for 50 days. The primary
tumor was removed during necropsy and fixed in forma-
lin then paraffin embedded, sectioned and stained with
H&E. Enlarged lymph nodes from the paralumbar region
were visualized under surgical microscopy and then dis-
sected out. These lymph nodes were then fixed, embedded
and histologically analyzed for prostate cancer cells.
Tissue immunostaining
Formalin-fixed prostate tumor tissues were paraffin
embedded, sectioned, applied to Plus slides (VWR Corp)
and then stained using a Dako autostainer system. The
slides were pre-treated with 3.0% hydrogen peroxide for
10 minutes, then rinsed and treated with a 10 μg/mL solu-
tion of proteinase K solution for 3 minutes to enhance
antigen retrieval. Next, non-specific binding sites were
blocked by addition of normal goat serum for 30 minutes
and then a 10 μg/mL solution of rabbit anti-human uPAR
(antibody 399R, American Diagnostica) or rabbit anti-
human Proliferating Cell Nuclear Antigen (AB15497,
AbCam antibodies) was applied to the tissue for 30 min-
utes. Primary antibody was removed by washing and then
appropriate horseradish peroxidase-labeled secondary
antibody was applied for a 30 minute period and was sub-
sequently detected using NovaRed substrate (Vector Labs,
Burlingame, CA) in a 8 minute incubation. Slides were
briefly counter stained using hematoxylin before drying.
Cells from slides of primary and lymph node sections
were scored as either positive or negative for uPAR. Four
regions of each slide were randomly selected and 20 cells
from each region were scored. Data was collected from 5
different mice and uPAR staining in tumors was compared
to lymph node metastases from the same mouse.
Plasmids constructs and transfection
The 1.0 kb coding region of human uPAR was amplified
using PCR from a pT7TSuPAR plasmid [[27], a gift from
Dr. K. Karico, U. Pennsylvania] then cloned into the pEF6/
V5 His TOPO plasmid using the pEF6/V5 His TOPO kit
(Invitrogen Corp). This plasmid transcribes target cDNA
using the EF-alpha promoter.
Cells were transfected using a liposome (Lipofectamine
2000, Invitrogen). PC-3M cells were transiently trans-
fected with 1.0 μg per 24-well of uPAR plasmid using 1.0
μL liposome. Transfection medium was changed after 8
hours. Approximately 15% of cells over-expressed uPAR
after a 2 day period using this procedure as determined by
immunofluorescence.
Two chamber migration and in vitro invasion assays
Using a PC-3M cell strain that we have previously trans-
fected and selected to express EGFP driven by the EF-alpha
promoter, the uPAR cDNA was transiently introduced
into the cells using liposomal transfection. Over-expres-
sion of uPAR was verified using immunostaining and flu-
orescent microscopy. Cells were then plated into the
upper chamber of 24-well compatible Fluro-Blok tran-
swell inserts (BD Falcon) using 200,000 cells per insert.
For invasion assays, these inserts were pre-coated with
25.0  μg per membrane of Matrigel (BD Falcon). Cells
placed on top of the Matrigel layer must degrade the extra-
cellular matrix to reach the transwell porous membrane
and then migrate through the pores to the chemoattract-
ant. Migration assays utilized uncoated transwells.
The inserts were placed into standard culture medium
supplemented with 25.0% fetal bovine serum to serve as
a chemoattractant. The bottom of the membrane was vis-
ually inspected after 2 days for appearance of the EGFP-
expressing cells indicative of cells traversing the mem-
brane. In order to quantitate the numbers of uPAR-over
expressing cells as a ratio of the total cells, the following
methodology was used. After a 2 day period, three inserts
were immunostained for uPAR by sequential submersion
in 0.4% paraformaldehyde fixation solution × 20 min-
utes, 0.1% Triton-X 100/PBS permeabilization solution ×
3 minutes, HBSS/2% goat serum blocking solution × 10
minutes, blocking solution with 2 μg/mL mouse anti-
human uPAR (MAB 807, R&D Systems) × 2 hours, HBSS
wash solution, blocking solution with 2 μL/mL Alexa
Fluor 595 goat anti-mouse secondary antibody × 1 hour,
PBS as a wash solution. The membrane in the transwell
was carefully removed from the transwell, inserted
between two coverslips and both the upper and lower
sides were viewed under epifluorescence. The Fluro Blok
membrane effectively blocks fluorescence from cells on
one side of the membrane from appearing on the other
side. Using the 20X objective, five fields of view were ran-
domly scored for cells showing uPAR-over expression
(seen as red cells) and total cells (seen as green).
Flow cytometry assay to assess uPAR induction during 
suspension culture
PC-3M cells from stock adherent cultures were removed
from surfaces with 0.4% EDTA in PBS, washed to remove
EDTA and resuspended in growth medium. Approxi-
mately 106 cells per tube were placed in 50-mL polypro-
pylene conical tubes to initiate apoptosis in suspension
[4]. Four sets of tubes were prepared each day for periods
of 5 days after which the cells and a freshly prepared con-
trol group (day 0) were prepared for flow cytometry. The
cells were pelleted, re-suspended in Hank's Buffered
Saline solution (HBSS) containing 2% goat serum and
then incubated with 2 μg/mL mouse anti-human uPARCancer Cell International 2006, 6:21 http://www.cancerci.com/content/6/1/21
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(R&D Systems) for 2 hours at 37°C. Cells were then
washed in HBSS and incubated with Alexa Fluor 610 – R-
phycoerythrin goat anti – mouse IgG conjugate secondary
antibody for one hour. The mean fluorescent intensity
(MFI) of uPAR expression on cells gated above back-
ground (M1) was calculated for the samples over the 5 day
time course.
Assay to determine anoikis
PC-3M cells were transiently transfected overnight. To ini-
tiate apoptosis as a result of detachment (anoikis), cells
were removed from culture surfaces with 0.4% EDTA in
PBS, washed to remove EDTA and resuspended in growth
medium supplemented with heat-inactivated FBS. This
cell suspension was placed in a 50-mL polypropylene con-
ical tube to prevent re-attachment [4] with a perforated
cap to allow air passage. Aliquots of the cell suspension
were analyzed each day over 3 days to determine rates of
anoikis.
A modification of a commercially available live-dead
assay system (Molecular Probes) was used to differentially
stain apoptotic and live PC-3M cells. A one mL aliquot of
cells was loaded with 10 μg/mL Calcein Blue AM (Molec-
ular Probes) for 20 minutes at 37°C. This esterified probe
is a marker for live cells as it penetrates cells with an intact
outer membrane and is hydrolyzed by intracellular este-
rases freeing the fluorescent Calcein blue (excitation peak
373 nm, emission peak 440 nm). The cell solution was
then treated with 1 ug/mL ethidium bromide, which read-
ily penetrates ruptured cell membranes intensely staining
the DNA. Ethidium staining of condensed nuclei is an
indication of late-stage apoptosis. The ethidium fluores-
cent can be excited at 510 nm and detected at 595 nm.
Cells were then briefly pelleted by centrifugation, the
medium was removed and replaced with PBS and the pel-
let was re-suspended. Cell samples were then viewed
using epifluorescence and at least 20 cells per objective
field were scored as either 1) apoptotic and wild-type
uPAR, 2) apoptotic and uPAR-over expressing, 3) live and
wild-type uPAR or 4) live and uPAR-over expressing. Nine
fields were scored for each sample. To identify cells with
over-expressed uPAR in the cell solution, the aliquoted
solution was incubated for 6 hours with 4 μg/mL mouse
anti-uPAR (R&D Systems MAB 807), then for an addi-
tional hour with goat anti-mouse Alexa Fluor 488. This
procedure resulted in the cell surface labeling of uPAR-
over expressing cells with a green fluorescent dye easily
distinguishable from the blue and orange spectra of the
live-dead stains. The uPAR levels in wild-type PC-3M cells
was very low compared with levels in transfected cells and
these wild-type cells did not demonstrate visible stain.
Immunofluorescence
Cells were fixed in ice cold paraformaldehyde for 10 min-
utes then permeabilized using a solution of 0.1% Triton
X-100 in PBS for 5 minutes. Nonspecific primary antibody
binding was reduced by first blocking the cells for 20 min-
utes using a solution of HBSS with 2% normal goat sera.
Primary antibody (anti uPAR monoclonal, R&D Systems
MAB 807) was then added for 1.5 hours, and after the cells
were washed, a fluorescent-tagged secondary antibody
(Alexa Fluor 488 or 594, Molecular Probes Inc.) was
applied. Fluorescence was imaged through a Zeiss Axio-
vert 200 fluorescent microscope and recorded through an
Olympus Q-Capture 5.1 mega pixel color digital camera.
Abbreviations
uPAR urokinase receptor
uPAR+ cells uPAR overexpressing cells
uPA urokinase-type plasminogen activator enzyme
EGFP enhanced green fluorescent protein
PCNA proliferating cell nuclear antigen
MEM minimal essential medium
H&E Hematoxylin and eosin stain
HBSS Hank's balanced salt solution
MFI mean fluorescent intensity
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